Armin W. Mäder
Gründer bei Qvanteq AG
Profil
Armin W.
Mäder is the founder and Chairman of Qvanteq AG, a company founded in 2009.
He is currently the Director at Neurotune AG.
Dr. Mäder has previously served as Chairman & Chief Executive Officer at Memo Therapeutics AG, Chief Operating Officer at AC Immune SA, and Chief Financial Officer at Institut Straumann AG.
He holds a graduate and doctorate degree from the Swiss Federal Institute of Technology and an MBA from the International Institute for Management Development.
Aktive Positionen von Armin W. Mäder
| Unternehmen | Position | Beginn |
|---|---|---|
Neurotune AG
 Neurotune AG Pharmaceuticals: MajorHealth Technology Neurotune AG develops medications for neuropathic pain and sarcopenia. The firm is developing treatments which modulate the connections between nerve cells and its target cells. The company was founded by Bruno Oesch in January 2005 and is headquartered in Schlieren-Zurich, Switzerland. | Direktor/Vorstandsmitglied | - |
Qvanteq AG
 Qvanteq AG BiotechnologyHealth Technology Qvanteq AG develops novel bioactive stents to address and overcome the clinical adverse. Its products include technology, intracranial stents, Qstent Periphry, and Qstent Coronary. The company was founded in 2009 and is headquartered in Zurich, Switzerland. | Gründer | 01.01.2009 |
Ehemalige bekannte Positionen von Armin W. Mäder
| Unternehmen | Position | Ende |
|---|---|---|
| AC IMMUNE SA | Geschäftsführer | - |
Memo Therapeutics AG
 Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Vorstandsvorsitzender | - |
Institut Straumann AG
 Institut Straumann AG Medical/Nursing ServicesHealth Services Institut Straumann AG operates a dentistry group. It engages in the research, development and manufacturing dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions. The company is headquartered in Basel, Switzerland. | Finanzdirektor/CFO | - |
Ausbildung von Armin W. Mäder
| International Institute for Management Development | Masters Business Admin |
| Swiss Federal Institute of Technology | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AC IMMUNE SA | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Neurotune AG
Neurotune AG Pharmaceuticals: MajorHealth Technology Neurotune AG develops medications for neuropathic pain and sarcopenia. The firm is developing treatments which modulate the connections between nerve cells and its target cells. The company was founded by Bruno Oesch in January 2005 and is headquartered in Schlieren-Zurich, Switzerland. | Health Technology |
Institut Straumann AG
Institut Straumann AG Medical/Nursing ServicesHealth Services Institut Straumann AG operates a dentistry group. It engages in the research, development and manufacturing dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions. The company is headquartered in Basel, Switzerland. | Health Services |
Memo Therapeutics AG
Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Health Technology |
Qvanteq AG
Qvanteq AG BiotechnologyHealth Technology Qvanteq AG develops novel bioactive stents to address and overcome the clinical adverse. Its products include technology, intracranial stents, Qstent Periphry, and Qstent Coronary. The company was founded in 2009 and is headquartered in Zurich, Switzerland. | Health Technology |
